Page last updated: 2024-09-05

lapatinib and letrozole

lapatinib has been researched along with letrozole in 37 studies

Compound Research Comparison

Studies
(lapatinib)
Trials
(lapatinib)
Recent Studies (post-2010)
(lapatinib)
Studies
(letrozole)
Trials
(letrozole)
Recent Studies (post-2010) (letrozole)
1,9193051,4422,6126121,602

Protein Interaction Comparison

ProteinTaxonomylapatinib (IC50)letrozole (IC50)
Steryl-sulfataseHomo sapiens (human)0.0009
AromataseHomo sapiens (human)0.009
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)2.62
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)1.42
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)0.0009

Research

Studies (37)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's5 (13.51)29.6817
2010's27 (72.97)24.3611
2020's5 (13.51)2.80

Authors

AuthorsStudies
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Conte, PF; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Oliva, C; Piacentini, F1
Arya, N; Chu, QS; Cianfrocca, ME; Fleming, RA; Gale, M; Goldstein, LJ; Koch, KM; Loftiss, J; Murray, N; Pandite, L; Paul, E; Rowinsky, EK1
Fricker, J1
Dieras, V; Florance, A; Gomez, HL; Johnston, S; Kennedy, MJ; Lichinitser, M; Maltzman, J; Manikhas, A; O'Rourke, L; Oliva, C; Pegram, M; Pippen, J; Pivot, X; Press, MF; Romieu, G; Sadeghi, S; Stein, S1
Guarneri, V1
Florance, A; Franco, SX; Johnston, S; Maltzman, J; O'Rourke, L; Schwartzberg, LS; Schwarzberg, LS1
Arnould, L; Coudert, B; Favier, L; Fumoleau, P; Guiu, S1
Curran, MP1
Amonkar, MM; Johnston, S; Maltzman, J; O'Rourke, L; Sherif, B; Sherrill, B2
Dobbins, TA; Drew, AK; Harris, CA; Pearson, S; Ward, RL1
de Azambuja, E; Metzger-Filho, O1
Armstrong, A; Bagust, A; Blundell, M; Boland, A; Davis, H; Dickson, R; Dundar, Y; Fleeman, N; Moonan, M; Oyee, J; Thorp, N1
Ito, Y1
Amonkar, MM; Diaz, JR; Forbes, CA; Kleijnen, J; Lykopoulos, K; Rea, DW; Riemsma, R1
Chang, JC; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Mayer, IA; Nanda, R; Osborne, CK; Pavlick, AC; Rimawi, MF; Rodriguez, AA; Schiff, R; Wang, T1
Chaigneau, L; Demarchi, M; Dobi, E; Merrouche, Y; N'guyen, T; Pivot, X; Romieu, G; Salvat, J; Villanueva, C; Vuillemin, AT1
Mehta, A; Tripathy, D1
Dering, J; Ellis, C; Finn, RS; Florance, A; Johnston, S; Martin, AM; O'Rourke, L; Press, MF1
Artioli, F; Bettelli, S; Bisagni, G; Boni, C; Bottini, A; Cagossi, K; Cavanna, L; Conte, P; Ellis, C; Ficarra, G; Frassoldati, A; Generali, DG; Guarneri, V; Holford, C; Maiorana, A; Nuzzo, S; Piacentini, F; Roncaglia, E; Swaby, R; Tagliafico, E1
Chandarlapaty, S; Crews, JR; Davidson, NE; Esteva, FJ; Giordano, SH; Gonzalez-Angulo, AM; Kirshner, JJ; Krop, I; Levinson, J; Lin, NU; Modi, S; Patt, DA; Perez, EA; Perlmutter, J; Ramakrishna, N; Temin, S; Winer, EP1
Harbeck, N1
Bregni, G; de Braud, F; Di Cosimo, S; Zanardi, E1
Beauchemin, C; Lachaine, J; Letarte, N; Mathurin, K; Yelle, L1
Adamo, B; Cheang, MC; Ellis, C; Gagnon, R; Galván, P; Johnston, S; Muñoz, M; Nuciforo, P; Paré, L; Prat, A; Press, MF; Viladot, M1
Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kang, MJ; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH1
Yamamoto, C; Yamamoto, D; Yamamoto, M1
Banna, G; Berardi, R; Bisagni, G; Cagossi, K; Cavanna, L; Conte, P; Dieci, MV; Ficarra, G; Frassoldati, A; Generali, D; Goubar, A; Griguolo, G; Guarneri, V; Michelotti, A; Piacentini, F; Puglisi, F1
De Angelis, C; Forero, A; Goetz, MP; Gutierrez, C; Hilsenbeck, SG; Jiralerspong, S; Krop, I; Nanda, R; Nangia, JR; Niravath, P; Osborne, CK; Pavlick, A; Rexer, BN; Rimawi, MF; Schiff, R; Storniolo, AM; Veeraraghavan, J; Wang, T; Wolff, AC1
Ahn, JH; Ahn, SH; Gong, G; Jung, KH; Kim, D; Kim, HH; Kim, JE; Kim, SB; Lee, HJ; Moon, DH; Park, JH; Shin, HJ; Son, BH1
Boué, SM; Burow, ME; Davidson, AM; Gupta, A; Khupse, R; Patel, JR; Payton-Stewart, F; Tilghman, SL; Walker, RR; Williams, CC1
Acconcia, F1
Banjara, B; Boué, SM; Burow, ME; Davidson, AM; Ohemeng, A; Patel, JR; Tilghman, SL1

Reviews

11 review(s) available for lapatinib and letrozole

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
    Expert review of anticancer therapy, 2009, Volume: 9, Issue:11

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles

2009
[Management of metastatic HER2-positive breast cancer: present and future].
    Bulletin du cancer, 2010, Volume: 97, Issue:3

    Topics: Anastrozole; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Bevacizumab; Brain Neoplasms; Breast Neoplasms; Disease Progression; Female; Heart; Humans; Lactams, Macrocyclic; Lapatinib; Letrozole; Neoplasm Proteins; Nitriles; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab; Triazoles

2010
Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer.
    Drugs, 2010, Jul-30, Volume: 70, Issue:11

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Triazoles

2010
The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:6

    Topics: Anastrozole; Anthracyclines; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome; Triazoles

2011
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis.
    Health technology assessment (Winchester, England), 2011, Volume: 15, Issue:42

    Topics: Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Cost-Benefit Analysis; Disease-Free Survival; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles

2011
[Progress of molecularly targeted therapy for breast cancer].
    [Rinsho ketsueki] The Japanese journal of clinical hematology, 2012, Volume: 53, Issue:4

    Topics: Ado-Trastuzumab Emtansine; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Denosumab; Drug Design; Drug Therapy, Combination; Everolimus; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2012
Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive(HR+) and HER2+ advanced or metastatic breast cancer(MBC).
    Current medical research and opinion, 2012, Volume: 28, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma; Disease Progression; Female; Humans; Lapatinib; Letrozole; Neoadjuvant Therapy; Neoplasm Metastasis; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Cytoplasmic and Nuclear; Triazoles

2012
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
    Breast (Edinburgh, Scotland), 2014, Volume: 23, Issue:1

    Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles

2014
Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Jul-01, Volume: 32, Issue:19

    Topics: Ado-Trastuzumab Emtansine; Anastrozole; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Comorbidity; Docetaxel; Drug Administration Schedule; Evidence-Based Medicine; Female; Health Status Disparities; Healthcare Disparities; Humans; Lapatinib; Letrozole; Maytansine; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Societies, Medical; Taxoids; Trastuzumab; Treatment Outcome; Triazoles; United States

2014
Better Together: Targeted Combination Therapies in Breast Cancer.
    Seminars in oncology, 2015, Volume: 42, Issue:6

    Topics: Androstadienes; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Resistance, Neoplasm; Everolimus; Female; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles

2015

Trials

12 trial(s) available for lapatinib and letrozole

ArticleYear
Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).
    Clinical breast cancer, 2008, Volume: 8, Issue:1

    Topics: Antineoplastic Agents; Breast Neoplasms; Double-Blind Method; Female; Genes, erbB-2; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Staging; Nitriles; Postmenopause; Quinazolines; Treatment Outcome; Triazoles

2008
A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jul-15, Volume: 14, Issue:14

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Nitriles; Ovarian Neoplasms; Quinazolines; Triazoles

2008
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-20, Volume: 27, Issue:33

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Nitriles; Postmenopause; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Risk Assessment; Survival Analysis; Treatment Outcome; Triazoles

2009
Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer.
    The oncologist, 2010, Volume: 15, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Synergism; Female; Humans; Lapatinib; Letrozole; Middle Aged; Nitriles; Placebos; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles

2010
Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinib.
    The oncologist, 2010, Volume: 15, Issue:9

    Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quality of Life; Quinazolines; Receptor, ErbB-2; Triazoles

2010
Quality-adjusted survival analysis of first-line treatment of hormone-receptor-positive HER2+ metastatic breast cancer with letrozole alone or in combination with lapatinib.
    Current medical research and opinion, 2011, Volume: 27, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease-Free Survival; Double-Blind Method; Female; Humans; Lapatinib; Letrozole; Nitriles; Quinazolines; Receptor, ErbB-2; Survival Rate; Triazoles

2011
Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, May-10, Volume: 31, Issue:14

    Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Humans; Lapatinib; Letrozole; Lymphatic Metastasis; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Triazoles; Up-Regulation

2013
Phase II study assessing lapatinib added to letrozole in patients with progressive disease under aromatase inhibitor in metastatic breast cancer-Study BES 06.
    Targeted oncology, 2013, Volume: 8, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoplasm Grading; Nitriles; Quinazolines; Receptor, ErbB-2; Treatment Outcome; Triazoles

2013
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Apr-01, Volume: 32, Issue:10

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; Double-Blind Method; Female; Humans; Ki-67 Antigen; Lapatinib; Letrozole; Middle Aged; Mutation; Neoadjuvant Therapy; Nitriles; Phosphatidylinositol 3-Kinases; Phosphorylation; Postmenopause; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Triazoles

2014
Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change after ne
    Cancer chemotherapy and pharmacology, 2016, Volume: 78, Issue:4

    Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Biomarkers, Tumor; Breast Neoplasms; Combined Modality Therapy; Female; Humans; Lapatinib; Letrozole; Lymphocyte Count; Lymphocytes, Tumor-Infiltrating; Mastectomy; Middle Aged; Neoadjuvant Therapy; Nitriles; Positron-Emission Tomography; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Triazoles

2016
TBCRC023: A Randomized Phase II Neoadjuvant Trial of Lapatinib Plus Trastuzumab Without Chemotherapy for 12 versus 24 Weeks in Patients with HER2-Positive Breast Cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 02-15, Volume: 26, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Female; Humans; Lapatinib; Letrozole; Middle Aged; Neoadjuvant Therapy; Receptor, ErbB-2; Receptors, Estrogen; Trastuzumab; Treatment Outcome; Young Adult

2020
Predictive Role of TP53, PIK3CA and MLL2 in ER+ HER2+ Breast Bancer: Biomarker Analysis of Neo-ALL-IN [NCT 01275859].
    Anticancer research, 2020, Volume: 40, Issue:10

    Topics: Aged; Biomarkers, Tumor; Breast; Breast Neoplasms; Class I Phosphatidylinositol 3-Kinases; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; Middle Aged; Mutation; Neoplasm Proteins; Progression-Free Survival; Receptor, ErbB-2; Tumor Suppressor Protein p53

2020

Other Studies

14 other study(ies) available for lapatinib and letrozole

ArticleYear
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
    Drug metabolism and disposition: the biological fate of chemicals, 2012, Volume: 40, Issue:12

    Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship

2012
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
San Antonio Breast Cancer Symposium.
    The Lancet. Oncology, 2009, Volume: 10, Issue:1

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Diphosphonates; Everolimus; Female; Humans; Imidazoles; Lapatinib; Letrozole; Nitriles; Quinazolines; Sirolimus; Tamoxifen; Trastuzumab; Triazoles; Zoledronic Acid

2009
Breast cancer drug approved for new indication.
    Women's health (London, England), 2010, Volume: 6, Issue:2

    Topics: Antineoplastic Agents; Breast Neoplasms; Drug Administration Schedule; Drug Approval; Drug Therapy, Combination; Female; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Triazoles; United States; United States Food and Drug Administration; Women's Health

2010
Neoadjuvant chemotherapy and targeted therapies: a promising strategy.
    Journal of the National Cancer Institute. Monographs, 2011, Volume: 2011, Issue:43

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Repair; Drug Discovery; Everolimus; Female; Genetic Predisposition to Disease; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Neoadjuvant Therapy; Nitriles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; Trastuzumab; Triazoles

2011
Quantitative ER and PgR assessment as predictors of benefit from lapatinib in postmenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-01, Volume: 20, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Female; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Neoplasm Metastasis; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Retrospective Studies; Triazoles

2014
Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
    Breast (Edinburgh, Scotland), 2015, Volume: 24 Suppl 2

    Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Female; Humans; Lapatinib; Letrozole; Molecular Imaging; Neoadjuvant Therapy; Nitriles; Precision Medicine; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Trastuzumab; Triazoles

2015
A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
    Journal of medical economics, 2016, Volume: 19, Issue:6

    Topics: Anastrozole; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Canada; Cost-Benefit Analysis; Disease Progression; Female; Health Services; Humans; Lapatinib; Letrozole; Markov Chains; Models, Econometric; Neoplasm Metastasis; Nitriles; Quality-Adjusted Life Years; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Terminal Care; Trastuzumab; Triazoles

2016
Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
    JAMA oncology, 2016, Oct-01, Volume: 2, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Breast Neoplasms; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Lapatinib; Letrozole; Middle Aged; Nitriles; Prognosis; Proportional Hazards Models; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Treatment Outcome; Triazoles

2016
[A Case of Interstitial Pneumonitis Induced by Lapatinib plus Letrozole].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2016, Volume: 43, Issue:12

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; ErbB Receptors; Female; Humans; Lapatinib; Letrozole; Lung Diseases, Interstitial; Nitriles; Quinazolines; Triazoles

2016
Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast cancer research and treatment, 2017, Volume: 163, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Female; Humans; Lapatinib; Letrozole; Lymphocytes, Tumor-Infiltrating; Middle Aged; Neoadjuvant Therapy; Nitriles; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Cell Surface; Treatment Outcome; Triazoles

2017
Glyceollins Trigger Anti-Proliferative Effects in Hormone-Dependent Aromatase-Inhibitor-Resistant Breast Cancer Cells through the Induction of Apoptosis.
    International journal of molecular sciences, 2022, Mar-07, Volume: 23, Issue:5

    Topics: Apoptosis; Aromatase; Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Neoplasm Recurrence, Local; Nitriles; Pterocarpans; Triazoles

2022
Evaluation of the Sensitivity of Breast Cancer Cell Lines to Cardiac Glycosides Unveils ATP1B3 as a Possible Biomarker for the Personalized Treatment of ERα Expressing Breast Cancers.
    International journal of molecular sciences, 2022, Sep-21, Volume: 23, Issue:19

    Topics: Adenosine Triphosphatases; Anastrozole; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Cardiac Glycosides; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Letrozole; MCF-7 Cells; Ouabain; Precision Medicine; Sodium-Potassium-Exchanging ATPase; Tamoxifen

2022
Novel Therapeutic Combination Targets the Growth of Letrozole-Resistant Breast Cancer through Decreased Cyclin B1.
    Nutrients, 2023, Mar-28, Volume: 15, Issue:7

    Topics: Aromatase Inhibitors; Breast Neoplasms; Cell Line, Tumor; Cyclin B1; Drug Resistance, Neoplasm; Estrogens; Female; Humans; Lapatinib; Letrozole; Mitogen-Activated Protein Kinases; Nitriles; Triazoles

2023